Comparing the Efficacy of Two Valved Holding Chambers in Acute Wheezing

Bronchospasm; Bronchitis Clinical Trial

— CHAMBER  

Official title:

Comparing the Efficacy of Two Valved Holding Chambers for Bronchodilator Administration in 0.5-4 Years Old Children With Acute Wheezing - a Randomized Clinical Trial

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT03900494
• Other study ID #: ETL-R19030
• Status: Recruiting
• Phase: N/A
• Start date: April 17, 2019
• Est. completion date: December 31, 2028

Study information

• Verified date: March 2024
• Source: Tampere University
• Contact: Peter Csonka, MD. PhD.
• Phone: +358503661103
• Email: peter.csonka[@]tuni.fi
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The incidence of physician confirmed asthma is approximately 4-7% in children. An additional 5% of children suffer from infection-related bronchiolitis and obstructive bronchitis. Of all patient visits at pediatric emergency rooms, 1 out of 10 is due to breathing difficulties with a great proportion leading to hospitalization. Salbutamol is the most commonly used drug in the treatment in acute bronchial obstruction. A vast majority of children require a spacer device (valved holding chamber, VHC) for the delivery of the drug aerosol. There are several different types of VHC on the market, but no recommendations on the device selection have been published. Both in in vivo and in vitro studies significant differences between different spacer devices have been reported. The study compares two different VHCs in the treatment of acute breathing difficulties in children. The end-points in this randomized physician-blinded study are symptom relief, rate of hospitalization, symptom recurrence, treatment compliance, and adverse events. The study will be conducted in pediatric emergency rooms (ER) in three university hospitals in Finland and one private clinic that routinely treat this type of patients. The treatment is given according to national treatment guidelines and no blood samples are drawn for study purposes. Both of the VHCs used in this study have been approved for use in clinical practice.

Description:

This study compares two valved holding chamber (VHC) devices in the treatment of acute airway obstruction in children. Eighty children (6 months to 4 years of age) will be recruited with moderate to severe dyspnea according to the Respiratory Distress Assessment Instrument (RDAI score ≥6). After receiving an informed consent from the parents/caregivers, the child is randomized to receive treatment with either Babyhaler® or Optichamber Diamond® VHC. Patients with underlying medical conditions listed in the study protocol, patients requiring immediate hospitalization or not willing to participate will be excluded from the study. Information on the medical history together with treatment response will be recorded using a manual case report form. According to calculations of the statistical power using the RDAI-score as an end-point, a total of 80 patients (40 patients in both study groups) are needed for the study. The study hypothesis is that the two VHCs are not equally efficient in treating acute shortage of breath in children aged 0.5-4 years.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 80
• Est. completion date: December 31, 2028
• Est. primary completion date: May 31, 2026
• Accepts healthy volunteers: No
• Gender: All
• Age group: 6 Months to 4 Years

Eligibility

Inclusion Criteria:

• Children (age 0.5-4 years) seeking medical aid due to respiratory distress caused by bronchial obstruction

Exclusion Criteria:

• requiring immediate admission to inpatient treatment in hospital
• peripheral capillary oxygen saturation below 85% on admission
• physician-confirmed pneumonia
• inspiratory crackles on lung auscultation
• croup
• airway foreign body
• impaired renal or liver function
• immune compromised patient
• general condition affecting the study per investigation judgement
• bronchopulmonary dysplasia
• long-acting beta-adrenoceptor agonist treatment
• recruited to the ongoing study earlier
• have been enrolled in a clinical trial within 30 days prior to admission
• not willing to participate

Related Conditions & MeSH terms

• Acute Disease
• Bronchial Spasm
• Bronchiolitis
• Bronchiolitis; Obstruction
• Bronchitis
• Bronchitis Obstructive
• Bronchospasm; Bronchitis
• Respiratory Sounds

Intervention

Device:
• VHC 1
Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 1. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.
• VHC 2
Salbutamol 0.6-0.8 mg given 20-40 min. maximum four times depending on the bronchodilator response delivered via valved holding chamber 2. Same salbutamol dosing protocol for both arms. Only difference is the VHC used.

Locations

Country	Name	City	State
Finland	Kuopio University Hospital	Kuopio
Finland	Oulu University Hospital	Oulu
Finland	Tampere University Hospital	Tampere
Finland	Terveystalo Tampere	Tampere

Sponsors (5)

Lead Sponsor	Collaborator
Tampere University	Kuopio University Hospital, Oulu University Hospital, Tampere University Hospital, Terveystalo Healthcare Services

Country where clinical trial is conducted

Finland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Number of subjects whose RDAI symptom score increase by 2 or more	Respiratory Distress Assessment Instrument (RDAI) score. Change from baseline at each evaluation point. Discharge time is dependent on the score at each evaluation point. Minimum score 0 (best), maximum score 17 (worst). Inclusion criteria is at least 6.	20 minutes after the second salbutamol-dose and if necessary 20 minutes after the third or fourth salbutamol-dose. Maximum 5 hours.
Primary	Difference in the mean capillary oxygen saturation change between groups	Peripheral capillary oxygen saturation (%). Change from baseline at each evaluation point. Minimum 85 % (if below, not suitable for the study), maximum 100 %.	20 minutes after the second salbutamol-dose and if necessary 20 minutes after the third or fourth salbutamol-dose. Maximum 5 hours.
Primary	Difference in the mean respiratory rate change between group	Respiratory rate per minute. Change from baseline at each evaluation point. Minimum N/A, maximum N/A.	20 minutes after the second salbutamol-dose and if necessary 20 minutes after the third or fourth salbutamol-dose. Maximum 5 hours.
Secondary	Compliance to treatment, compared between groups	Compliance to the treatment using a structured questionnaire conducted both by the parents and by the nurses treating the child in the emergency room.; Cooperation score from 0 to 5: 0 = no measurement possible; 1 = continuously crying, screaming, or struggling against the procedure; 2 = crying, screaming, or struggling, but not continuously; 3 = not very good cooperation, but no crying or screaming; 4 = good cooperation, but clearly not comfortable; 5 = good cooperation and quiet breathing during the whole measurement.	Throughout the ER visit. Maximum 5 hours.
Secondary	Number of subjects hospitalized in both group	The information on whether the patient is discharged from the emergency room or admitted to hospital for further treatment will be recorded in the case report form.	After the last dose of salbutamol. Maximum 5 hours.
Secondary	Readmission rate in both group	Re-hospitalization within 48 hours of initial treatment based on patient records.	Within 48 hours of initial treatment.
Secondary	Number of drug doses given in both groups	Number of salbutamol-doses given to the patient. Minimum two, maximum four doses. Less dose is better.	Throughout the ER visit. Maximum 5 hours.
Secondary	Difference in the mean heart rate change between groups	Change in heart rate per minute. Minimum N/A, maximum N/A.	After each salbutamol dose. Maximum 5 hours.